A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)

Cancer Immunology, Immunotherapy

Volumn 64, Issue 3, 2015, Pages 367-379

  Zandberg, Dan P ^a,b   Rollins, Sandra ^b   Goloubeva, Olga ^a   Morales, Robert E ^b   Tan, Ming ^c   Taylor, Rodney ^b   Wolf, Jeffrey S ^b   Schumaker, Lisa M ^a   Cullen, Kevin J ^a,b   Zimrin, Ann ^a,b   Ord, Robert ^a,b   Lubek, Joshua E ^a,b   Suntharalingam, Mohan ^b   Papadimitriou, John C ^b   Mann, Dean ^b   Strome, Scott E ^b   Edelman, Martin J ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Immune response; Peptide; Squamous cell carcinoma of the head and neck; Vaccine

Indexed keywords

CANCER VACCINE; GL 0810; GL 0817; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELANOMA ANTIGEN 3; MONTANIDE ISA 51; PEPTIDE VACCINE; UNCLASSIFIED DRUG; WART VIRUS VACCINE; IMMUNOLOGIC FACTOR; MAGEA3 PROTEIN, HUMAN; SUBUNIT VACCINE; TUMOR ANTIGEN; TUMOR PROTEIN;

ADJUVANT THERAPY; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTHRALGIA; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER RECURRENCE; CANCER SURVIVAL; CHILL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FLU LIKE SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PHARYNGOCUTANEOUS FISTULA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; RECURRENT MATASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA; SKIN FISTULA; T LYMPHOCYTE; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; DOSE RESPONSE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGY; MIDDLE AGED;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; VACCINES, SUBUNIT;

EID: 84925511280     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1640-x     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi:10.3322/caac.20107
2. McDonald MW, Lawson J, Garg MK et al (2011) ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys 80:1292–1298. doi:10.1016/j.ijrobp.2011.02.014
3. Vermorken JB, Specenier P (2010) Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 21 Suppl 7: vii252–261. doi 10.1093/annonc/mdq453
4. Gillison ML, Koch WM, Capone RB et al (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709–720. doi:10.1093/jnci/92.9.709
5. Kreimer AR, Clifford GM, Boyle P, Franceschi S (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14:467–475. doi:10.1007/s12105-010-0171-9
6. Munoz N, Bosch FX, de Sanjose S et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527. doi:10.1056/NEJMoa021641
7. Kenter GG, Welters MJ, Valentijn AR et al (2008) Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 14:169–177. doi:10.1158/1078-0432.CCR-07-1881
8. Ressing ME, Sette A, Brandt RM et al (1995) Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154:5934–5943
9. van der Burg SH, Ressing ME, Kwappenberg KM et al (2001) Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 91:612–618. doi:10.1002/1097-0215
10. Cuffel C, Rivals JP, Zaugg Y et al (2011) Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer 128:2625–2634. doi:10.1002/ijc.25607
11. Figueiredo DL, Mamede RC, Spagnoli GC et al (2011) High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head Neck 33:702–707. doi:10.1002/hed.21522
12. Jungbluth AA, Ely S, DiLiberto M et al (2005) The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 106:167–174. doi:10.1182/blood-2004-12-4931
13. Condomines M, Hose D, Raynaud P et al (2007) Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol 178:3307–3315. doi:10.4049/jimmunol.178.5.3307
14. van der Bruggen P, Traversari C, Chomez P et al (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647. doi:10.1126/science.1840703
15. Kobayashi H, Song Y, Hoon DS et al (2001) Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 61:4773–4778
16. Lu J, Wettstein PJ, Higashimoto Y et al (2001) TAP-independent presentation of CTL epitopes by Trojan antigens. J Immunol 166:7063–7071. doi:10.4049/jimmunol.166.12.7063
17. Lu J, Higashimoto Y, Appella E, Celis E (2004) Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol 172:4575–4582. doi:10.4049/jimmunol.172.7.4575
18. Voskens CJ, Sewell D, Hertzano R et al (2012) Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck 34:1734–1746. doi:10.1002/hed.22004
19. Fruh K, Yang Y (1999) Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol 11:76–81. doi:10.1016/S0952-7915(99)80014-4
20. Cheever MA, Chen W (1997) Therapy with cultured T cells: principles revisited. Immunol Rev 157:177–194. doi:10.1111/j.1600-065X.1997.tb00982.x
21. Gao FG, Khammanivong V, Liu WJ et al (2002) Antigen-specific CD4 + T-cell help is required to activate a memory CD8 + T cell to a fully functional tumor killer cell. Cancer Res 62:6438–6441
22. Voskens CJ, Strome SE, Sewell DA (2009) Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome. Curr Mol Med 9:683–693
23. Pichichero ME (2008) Improving vaccine delivery using novel adjuvant systems. Hum Vaccin 4:262–270. doi:10.4161/hv.4.4.5742
24. Kreimer AR, Johansson M, Waterboer T et al (2013) Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 31:2708–2715. doi:10.1200/JCO.2012.47.2738
25. Kruit WH, van Ojik HH, Brichard VG et al (2005) Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 117:596–604. doi:10.1002/ijc.21264
26. Klebanoff CA, Acquavella N, Yu Z, Restifo NP (2011) Therapeutic cancer vaccines: are we there yet? Immunol Rev 239:27–44. doi:10.1111/j.1600-065X.2010.00979.x
27. Atanackovic D, Altorki NK, Stockert E et al (2004) Vaccine-induced CD4 + T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 172:3289–3296. doi:10.4049/jimmunol.172.5.3289
28. Vansteenkiste J, Zielinski M, Linder A et al (2013) Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 31:2396–2403. doi:10.1200/JCO.2012.43.7103
29. Marchand M, Punt CJ, Aamdal S et al (2003) Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 39:70–77. doi:10.1016/S0959-8049(02)00479-3
30. Kruit WH, Suciu S, Dreno B et al (2013) Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 31:2413–2420. doi:10.1200/JCO.2012.43.7111
31. Brinkman JA, Hughes SH, Stone P et al (2007) Therapeutic vaccination for HPV induced cervical cancers. Dis Markers 23:337–352. doi:10.1155/2007/245146
32. Allen CT, Judd NP, Bui JD, Uppaluri R (2012) The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope 122:144–157. doi:10.1002/lary.21913
33. Young MR (2006) Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck 28:462–470. doi:10.1002/hed.20331
34. Lyford-Pike S, Peng S, Young GD et al (2013) Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 73:1733–1741. doi:10.1158/0008-5472.CAN-12-2384
35. Strome SE, Dong H, Tamura H et al (2003) B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 63:6501–6505
36. Ukpo OC, Thorstad WL, Lewis JS Jr (2012) B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol 7:113–121. doi:10.1007/s12105-012-0406-z
37. Li W, Deng XM, Wang CX et al (2010) Down-regulation of HLA class I antigen in human papillomavirus type 16 E7 expressing HaCaT cells: correlate with TAP-1 expression. Int J Gynecol Cancer 20:227–232. doi:10.1111/IGC.0b013e3181cceec5
38. Campo MS, Graham SV, Cortese MS et al (2010) HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 407:137–142. doi:10.1016/j.virol.2010.07.044
39. Schott AK, Pries R, Wollenberg B (2010) Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer. Int J Mol Med 26:67–75. doi:10.3892/ijmm_00000436
40. Strauss L, Bergmann C, Szczepanski M et al (2007) A unique subset of CD4 + CD25highFoxp3 + T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13:4345–4354. doi:10.1158/1078-0432.CCR-07-0472
41. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22:275–281. doi:10.1016/j.semcancer.2012.01.011
42. Herbst RS, Arquette M, Shin DM et al (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23:5578–5587. doi:10.1200/JCO.2005.07.120
43. Zenda S, Onozawa Y, Boku N et al (2007) Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). Jpn J Clin Oncol 37:477–481. doi:10.1093/jjco/hym059
44. Le DT, Jaffee EM (2012) Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 72:3439–3444. doi:10.1158/0008-5472.CAN-11-3912
45. Lutsiak ME, Semnani RT, De Pascalis R et al (2005) Inhibition of CD4(+)25 + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862–2868. doi:10.1182/blood-2004-06-2410